Navigation Links
Ampio Responds to Levi & Korsinsky, LLP Press release/solicitation
Date:11/19/2013

GREENWOOD VILLAGE, Colo., Nov. 19, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) CEO, Michael Macaluso, remarked "We are not aware of any basis for an investigation of Ampio. We note that the law firm's press release/solicitation does not contain any facts whatsoever that would explain why they are conducting an investigation.  Any objective review of Ampio's promising clinical trial results and subsequent stock performance achieved over the past year will conclude that the company is performing well.  Consequently we believe this provocative solicitation is not intended to benefit shareholders and we encourage all interested parties to form their own conclusions about the motivation behind this law firm's actions."

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contact:  Rick Giles, Director of Investor Relations, Ampio Pharmaceuticals, Inc.  Direct: (720) 437-6530, Email: rgiles@ampiopharma.com

 

 

 


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
2. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
3. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
4. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
5. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
6. CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"
7. Champions Oncology Reports Financial Results for the Quarter Ended October 31, 2012
8. North Carolina A&T State University Crowned Champion in $100,000 ACC Clean Energy Challenge
9. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
10. GenoSpace Founder and CEO Receives "Champions of Change" Award from White House
11. Olympic Champion and Health and Fitness Advocate Dara Torres Partners with Vestiage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... New FDA action date of July 22, 2016 ... 22, 2016   --> - New ... - Lifitegrast has the potential to be the only product ... signs and symptoms of dry eye disease in adults --> ... in the U.S. in the past decade indicated for the treatment of signs ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... and commercialization of targeted antiviral therapies, announced today that ... 2016, to be held February 8-9, 2016, at the ... Disruptive Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):